The 2019 Scheele Symposium: CRISPR-Cas and gene therapy
Welcome to the Scheele Symposium in honour of the 2019 Scheele Award Laureate, Professor Emmanuelle Charpentier. The symposium focuses on various aspects of her research, including insights into the CRISPR-Cas technology, which has paved the way for development of new, effective treatments. Take this opportunity to listen to some of the world’s foremost scientists in genetic engineering.
On November 28, 2019, the Scheele Symposium will be held in Näringslivets Hus, Storgatan 19, Stockholm.
About the award winner
Professor Emmanuelle Charpentier, head of the Max Planck Unit for the Science of Pathogens in Berlin, is a pioneer in gene regulation in pathogenic bacteria and mechanisms that involve short sequences of ribonucleic acid. She is receiving the award for her “contribution to understanding the molecular mechanism of the CRISPR-Cas9 system – a genetic tool with several applications in drug research and development”.
“Professor Charpentier is a true innovator whose research may result in a real paradigm shift in biomedical gene therapies for many, severe, genetic disorders – including cystic fibrosis, hemophilia,and certain cancer forms,” said Karin Meyer, CEO of the Swedish Pharmaceutical Society and chair of the Scheele Award nomination committee.
About the Scheele Award and Symposium
Since 1961, in honour of Carl Wilhelm Scheele, famous Swedish chemist and pharmacist, the Swedish Pharmaceutical Society has bestowed the Scheele Award on prominent scientists in drug research or related disciplines. By tradition, a symposium focused on the prize winner’s area of expertise follows the award ceremony.
More information on the Scheele Award at Swedish Pharmaceutical Society